EpiWatch is an FDA-cleared seizure monitoring and alerting app for Apple Watch, designed for individuals with epilepsy and their caregivers.
The App DNA
What makes this app unique?
The app removes the cognitive and physical burden of manual seizure monitoring by automating alerts to caregivers, providing peace of mind for families who rely on clinical-grade safety tools.
For Individuals with epilepsy and their caregivers seeking clinically validated, wearable-based seizure monitoring and alerting.
Key features
Algorithm detects tonic-clonic seizure activity using Apple Watch sensors, serving as a brand moat that justifies the $19.99/month subscription.
Sends automated alerts via phone call, text, and email with GPS data, acting as a retention lever for families.
Enables independent Apple Watch use without a personal iPhone, creating a distribution barrier for non-smartphone users.
How much does it cost?
Subscription-only model anchored at $19.99/month, requiring a U.S. clinician prescription for account activation.
Velocity
Maintenance developmentUX improvementsperformanceplatform expansionShow more...
EpiWatch maintains a maintenance-level cadence, with 4 releases over the last 6 months averaging approximately one update every 6 to 7 weeks. Development is currently focused on stability, timezone corrections, and Apple Watch integration refinements. While the app previously introduced significant features like standalone watch support and a seizure diary, the recent trend has shifted toward minor maintenance and bug resolution. The Android platform remains significantly behind the iOS release cycle, with no updates in over 700 days.
Who built it?
User Sentiment
What do users think recently?
How are ratings & reviews evolving?
Not enough recent reviews to extract reliable themes yet.
Read the full review analysisCompetition
Competitive landscape for EpiWatch - Seizure Monitor
How's the Medical market?
EpiWatch holds a #29 Grossing position in the medical category, reflecting a specialized clinical focus. The requirement for a U.S. clinician prescription creates a high barrier to entry that limits broad consumer adoption but reinforces its medical-grade positioning.
Read the market outlookThe rivals identified
Unlock the deeper market read.
Access the full report for freeThe Analyst's Read
Key takeaways for EpiWatch - Seizure Monitor
Where is it heading?
The medical-grade wearable market is consolidating around clinically validated solutions, favoring apps that maintain high regulatory compliance. EpiWatch remains advantaged by its FDA clearance, but the current maintenance-only cadence leaves it exposed to competitors with faster iteration cycles.
- The 111-day update gap indicates a maintenance-mode posture, which limits feature expansion but preserves the core clinical-grade utility.
The SWOT
- FDA-cleared algorithm functions as a defensible barrier against consumer-grade rivals
- International market expansion could unlock revenue beyond the U.S. prescription-only model
Next best moves
Audit technical stability because the 111-day update gap risks user churn → maintain rating baseline
The counter-intuitive read
The prescription-only requirement is a feature, not a bug: it filters for high-intent…
Read the full takeSince the last report: EpiWatch has shifted from an active development phase to a maintenance-only posture, with a 111-day update gap now defining its competitive outlook. This transition highlights a move toward preserving existing clinical-grade utility at the expense of iterative feature growth.
Bottom line
Maintaining the current clinical-grade validation is the primary retention lever, but the 111-day update gap risks losing the technical edge to more agile entrants.
Unlock 1 critical friction, 1 market threat and the analyst’s take.
Access the full report for freeSources
Report last updated